despite the oxidizing reaction conditions. In addition to
cyclic amines, secondary aliphatic amines can be used in
this transformation (3pꢀ3s). In addition to simple dialkyl-
amines, synthetically more useful diallylamine and
dibenzylamine are tolerated. Undesired oxidations or ha-
logenations of the double bonds, the aromatic ring, or the
methylene units have not been observed. Furthermore we
were pleased to find that with TBHP even a primary amine
such as butyl amine could be used in our amination
procedure to yield 3t in a good yield of 69%.
Scheme 4. Amination of Benzoxazole with Various Aminesa
These promising results prompted us to investigate
our novel method toward the synthesis of the coumarin
derivative 5. 5 is known for its potent anti-HIV and
antitumor activity, and an efficient late stage arylation of
the piperazyl moiety of the potential precursor 4 would
give an easy access to various N-aryl derivatives.12 To our
delight our standard reaction protocol using aq H2O2
yielded 5 in a good yield of 59% under mild reaction
conditions (Scheme 5).
Scheme 5. TAAI-Mediated Synthesis of the Anti-HIV
Reagent 5a
a General reaction conditions: Method A: 0.336 mmol of 1a, 0.672
mmol of 2, 5 equiv of H2O2 (30% aq solution), 5 equiv of HOAc in 1 mL
of acetonitrile. Method B: 0.336 of mmol 1a, 0.403 mmol of 2, 1.5 equiv
of TBHP (70% aq solution), 3 equiv of AcOH in 1 mL of acetonitrile
at 80 °C.
Alkyl- and halogen-substituted benzoxazoles could be
aminated in perfect regioselectivity to yield the desired
2-(morpholino)benzoxazoles 3aꢀ3f in up to 86% yield.
Reaction of naphtho[1,2-d]oxazole with morpholine
yielded 2-aminonaphthooxazole 3e in an excellent yield
of 93%. Even the electron-poor 6-nitrobenzoxazole could
be derivatized to 3g, however with decreased yields. Here a
significant difference in yields (18% and 52%) was recog-
nized between the two oxidation reagents. Even though
yields were comparable when using H2O2 or TBHP as co-
oxidants, in the latter case a full conversion was observed
after 1 h for all substrates.
Next we discovered the reaction between various
linear and cyclic secondary amines and benzoxazole 1a
(Scheme 4). In addition to morpholine we could efficiently
use pyrrolidine, piperidine, and azepane for our oxidative
amination procedure. The desired products 3jꢀ3l were
obtained in 57ꢀ62% yield. Furthermore we could syn-
thesize 2-piperazylbenzoxazoles 3m and 3n in excellent
yields starting from N-methyl and N-acylpiperazine.
2-(N-alkylpiperazyl)benzoxazoles of this type were already
described as potent 5-HT3-receptor agonists.11 To our
surprise an unprotected hydroxyl group attached to the
N-alkyl residue of piperazine is tolerated as well (3o),
a Reaction conditions: Method A: 0.336 mmol of 1a, 2 equiv of 4, 5
equiv of H2O2 (30% aq solution), 5 equiv of HOAc, 1 mL of acetonitrile.
Method B: 0.336 mmol of 1a, 0.336 mmol (1.0 equiv) of 4, 1.5 equiv of
TBHP (70% aq solution) in 1 mL of acetonitrile at 80 °C.
After we examined a satisfying substrate scope we
performed several synthetic experiments to unravel the
underlying reaction mechanism. Addition of the radical
scavenger TEMPO (2,2,6,6-tetramethylpiperidine-N-oxyl)
had only a slight impact on the yield of 3a (58%).
Furthermore no TEMPO-bound intermediate could be
observed. Thus a radical mechanism can be ruled out.
Since catalytic amounts of I2 (without co-oxidant) did not
yield 3a, the in situ generation of I2 and its subsequent
function as a mild Lewis acid is also excluded.
Next we tried to examine the reactivity of iodine in the
oxidation state þ1 (Scheme 6). Stoichiometric amounts of
ICl, a potent source for iodonium ions (IR2þ), yielded 3a in
65% yield. Thusa mechanismthatpassesthroughIþ seems
plausible. Subsequently we wanted to verify whether in
(12) Al-Soud, Y. A.; Al-Sa’doni, H. H.; Amajaour, H. A. S.; Salih,
K. S. M.; Mubarak, M. S.; Al-Masoudi, N. A.; Jaber, I. H. Z.
Naturforsch. 2008, 63b, 83.
(ꢀ13) The potential in situ generation of ammonium(hypo)iodites
(IO /IO2ꢀ) as catalytically active species cannot be ruled out at this
point and is part of further investigations.
(14) Urbansky, E. T.; Cooper, B. T.; Margerum, D. W. Inorg. Chem.
1997, 36, 1338.
(11) (a) Yoshida, S.; Shiokawa, S.; Kawano, K.-I.; Ito, T.;
Murakami, H.; Suzuki, H.; Sato, Y. J. Med. Chem. 2005, 48, 7075.
(b) Sato, Y.; Imai, M.; Amano, K.; Iwamatsu, K.; Konno, F.; Kurata,
Y.; Sakakibara, S.; Hachisu, M.; Izumi, M.; Matsuki, N.; Saito, H. Biol.
Pharm. Bull. 1997, 20, 752.
3756
Org. Lett., Vol. 13, No. 14, 2011